This trial is testing a new drug, OBP-301, to see if it can help treat stomach and esophageal cancer that has gotten worse despite other treatments.
- Esophageal Cancer
1 Primary · 4 Secondary · Reporting Duration: 2 year
Awards & Highlights
1 Treatment Group
1 of 1
41 Total Participants · 1 Treatment Group
Primary Treatment: Telomelysin · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How potentially hazardous is Telomelysin for individuals receiving treatment?
"After assessing the safety profile of Telomelysin, our team at Power has assigned it a rating of 2. This is because Phase 2 trials have only provided limited evidence in regards to its efficacy and lack data concerning its hazard potential." - Anonymous Online Contributor
How many participants are actively engaged in this clinical endeavor?
"Oncolys BioPharma Inc's clinical trial necessitates 41 participants that adhere to the set inclusion criteria. The study will take place at well-known medical centres including Dana-Farber Cancer Institute in Boston, Massachusetts and University of Pennsylvania in Philadelphia, Pennsylvania." - Anonymous Online Contributor
Is this trial open to enrollment of participants at present?
"Indeed, clinicaltrials.gov data indicates that the study is now recruiting participants; it was initially published on May 9th 2019 and last revised April 29th 2022. The medical trial seeks to enrol 41 patients from 4 distinct sites." - Anonymous Online Contributor